View Tips and Talking Points for Supporting a Patient’s Decision
Posted May 12, 2025
Explore the latest actively enrolling clinical trials from Sylvester Comprehensive Cancer Center at the University of Miami Health System. These cutting-edge studies offer patients access to innovative treatments and contribute to advancing cancer research. Stay informed about trial opportunities across a wide range of cancer types and stages. Read More »
Posted February 11, 2025
This phase I trial tests the safety and side effects of yttrium-90 (Y90) radioembolization combined with immunotherapy drugs tremelimumab and durvalumab in treating patients with intrahepatic cholangiocarcinoma (cancer of the bile ducts in the liver) that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be removed by surgery (unresectable) who are... Read More »
Posted December 27, 2024
A Phase 2 Study of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Untreated CD123+ Acute Myeloid Leukemia (AML) Who Cannot Undergo Intensive Chemotherapy This multicenter open-label phase 2 study will evaluate Tagraxofusp (TAG) in combination with Venetoclax and Azacitidine (Ven/Aza) in adults with previously untreated CD123+ AML who are ineligible for intensive... Read More »
Posted November 22, 2024
Despite advances in the adjuvant treatment of early-stage estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, there continues to be a risk of recurrence. The ELEGANT study is a Global, Multicenter, Randomized, Open-label Phase 3 Study with the primary goal to evaluate the efficacy and safety of elacestrant versus standard endocrine... Read More »
Posted May 20, 2024
This international, randomized, open-label, Phase 3 study will compare the investigational combination of avutometinib plus defactinib versus Investigator’s Choice of Treatments (ICT) in patients with recurrent LGSOC who have progressed on a prior platinum-based therapy. Avutometinib and defactinib are both a type of drug called a kinase inhibitor. Kinase inhibitors block cancer cell growth. The... Read More »
© 2021 FLASCO | Premium Website Design by The HDG
